United Biopharma expands in China with a MAb facility in Yangzhou

13 March 2018

Taipei, Taiwan-based United Biopharma (UBP) partnered with GE Healthcare Life Sciences to build a biologics facility in Yangzhou, Jiangsu province, mainland China, reports The Pharma Letter’s correspondent Wang Fangqing.

With an initial investment of about 250 million renminbi ($39.4 million), the facility is equipped with 2x200L, 3x500L and 2x2000L single-use bioreactors. Complying with China’s Good Manufacturing Practices (GMP) and US current GMP standards, the facility is expected to test run n June 2019.

Initially, the Yangzhou facility is to manufacturer monoclonal antibodies (MAbs) for the Chinese market, said PJ Chen, UBP vice president who oversees business development in the mainland, where UBP has formed two subsidiaries with its key investors in Shanghai and Yangzhou to lead the China business.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK